| Q42284131 | A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study |
| Q38739489 | Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts |
| Q41925505 | Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail |
| Q46154949 | Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range |
| Q70866994 | Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine |
| Q34389048 | Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding |
| Q34302606 | Dapsone-Induced Hemolytic Anemia |
| Q48098830 | Dapsone-induced agranulocytosis-possible involvement of low-activity N-acetyltransferase 2. |
| Q50524075 | Dapsone-induced methemoglobinemia. |
| Q63859630 | Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus |
| Q51432740 | Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. |
| Q71691491 | Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole |
| Q58880651 | Effect of Conjugated Equine Estrogens on Oxidative Metabolism in Middle-aged and Elderly Postmenopausal Women |
| Q46038612 | Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. |
| Q41906399 | Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects |
| Q39966340 | Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer |
| Q33433952 | Extracorporeal treatments in a dapsone overdose: a case report |
| Q33666873 | How Clinically Relevant is Dapsone-related Peripheral Neuropathy?: An Overview of Available Data with Emphasis on Clinical Recognition. |
| Q30818645 | Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data |
| Q35821124 | Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis |
| Q39004668 | Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications |
| Q34624647 | Pharmacogenetics of the arylamine N-acetyltransferases. |
| Q36964648 | Pharmacokinetic considerations in clinical toxicology: clinical applications |
| Q40913176 | Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia |
| Q33977967 | Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children |
| Q59692451 | Pharmacokinetics of dapsone in children |
| Q35114401 | Pharmacokinetics of dapsone in human immunodeficiency virus-infected children |
| Q35129919 | Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. |
| Q62232369 | Structural basis for the haemotoxicity of dapsone: the importance of the sulphonyl group |
| Q78194451 | The effect of pregnenolone 16alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats |
| Q34403177 | The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients |
| Q62232458 | Use of a metabolic inhibitor to reduce dapsone-dependent haematological toxicity |
| Q41361472 | Use of probe drugs as predictors of drug metabolism in humans |
| Q73846452 | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes |
| Q39782074 | Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection |